Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of “Buy” by Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned a consensus recommendation of “Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $20.83.

A number of equities research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partners assumed coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th.

Stoke Therapeutics Trading Up 1.4 %

Shares of STOK opened at $11.43 on Friday. Stoke Therapeutics has a 1 year low of $3.77 and a 1 year high of $17.58. The stock has a 50 day simple moving average of $12.73 and a 200-day simple moving average of $13.79. The stock has a market cap of $605.45 million, a PE ratio of -5.44 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. On average, sell-side analysts forecast that Stoke Therapeutics will post -2.03 EPS for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the sale, the insider now owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This trade represents a 17.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Quest Partners LLC acquired a new stake in shares of Stoke Therapeutics in the second quarter valued at about $29,000. Nisa Investment Advisors LLC increased its position in shares of Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after acquiring an additional 1,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Stoke Therapeutics in the second quarter valued at about $123,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Stoke Therapeutics in the first quarter valued at about $141,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Stoke Therapeutics in the third quarter valued at about $160,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.